Download PDF
Thromb Haemost 1999; 82(05): 1558-1559
DOI: 10.1055/s-0037-1614877
Letters to the Editor
Schattauer GmbH

A Case of Type 2B von Willebrand Disease Reverse to Normal when Treated with High Doses of Protease Inhibitor

Yale S. Arkel
1   From the Blood Disorder Center for Hemostasis and Thrombosis, Overlook Hospital, Summit, New Jersey, USA
,
De-Hui W. Ku
1   From the Blood Disorder Center for Hemostasis and Thrombosis, Overlook Hospital, Summit, New Jersey, USA
,
Cathryn Lake
1   From the Blood Disorder Center for Hemostasis and Thrombosis, Overlook Hospital, Summit, New Jersey, USA
,
Lucy Pasquale
1   From the Blood Disorder Center for Hemostasis and Thrombosis, Overlook Hospital, Summit, New Jersey, USA
,
Xuan Lam
1   From the Blood Disorder Center for Hemostasis and Thrombosis, Overlook Hospital, Summit, New Jersey, USA
,
Deborah Gibson
1   From the Blood Disorder Center for Hemostasis and Thrombosis, Overlook Hospital, Summit, New Jersey, USA
,
Stuart Burstin
1   From the Blood Disorder Center for Hemostasis and Thrombosis, Overlook Hospital, Summit, New Jersey, USA
› Author Affiliations
Further Information

Publication History

Received 05 May 1999

Accepted after revision 07 July 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Ginsberg D, Sadler JE. VWD a database of point mutations, insertions and deletions. Thromb Haemost 1993; 69: 177-84.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Verweij CL, Quadt R, Briet E, Dubbledam K, van Ommen GB, Pannekoek H. Genetic linkage of two intragenic restriction fragment length polymorphisms with vWD type IIA. J Clin Invest 1988; 81: 1116-21.
    CrossrefPubMedGoogle Scholar
  • 3 Lyons SE, Bruck ME, Bowie EJW, Ginsberg D. Impaired intracellular transport produced by a subset of type IIA vWD mutations. J Biol Chem 1992; 267: 4424-30.
    PubMedGoogle Scholar
  • 4 Gaucher C, Dieval J, Mazurier C. Characterization of vWF gene defect in two unrelated patients with type IIC vWD. Blood 1994; 84: 1024-30.
    PubMedGoogle Scholar
  • 5 Gralnick HR, Williams SB, McKeown LP, Maisonneuve P, Jenneau C, Sultan Y. A variant of type II vWD with an abnormal triplet structure and discordant effects of protease inhibitor on plasma and platelet vW factor structure. Amer J Hematol 1987; 24: 259-66.
    CrossrefPubMedGoogle Scholar
  • 6 Cooney KA, Nichols W, Bruck M, Bahou W, Shapiro A, Bowie EJW, Gralnick H, Ginsberg D. The molecular defect in type IIB vWD. J Clin Invest 1991; 87: 1227-33.
    CrossrefPubMedGoogle Scholar
  • 7 Arkel Y, Desposito F. vWD with thrombocytopenia, platelet function defect and an abnormal factor VIII/vWF. Am J Ped Hematol/Oncol 1982; 4: 249-57.
    PubMedGoogle Scholar